A5004124237- Pulmonary Hypertension Research and Treatments
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Vascular Anomalies and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Liver Disease Diagnosis and Treatment
- Cardiovascular Issues in Pregnancy
- Transplantation: Methods and Outcomes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Heart Failure Treatment and Management
- Tracheal and airway disorders
- Cardiovascular Function and Risk Factors
- Medical Imaging and Pathology Studies
- Blood Pressure and Hypertension Studies
- Congenital Heart Disease Studies
- Renal function and acid-base balance
- Venous Thromboembolism Diagnosis and Management
- Cardiac Valve Diseases and Treatments
- Renin-Angiotensin System Studies
- Heme Oxygenase-1 and Carbon Monoxide
- Airway Management and Intubation Techniques
- Cardiac Structural Anomalies and Repair
- Advanced Sensor and Control Systems
- Heart Rate Variability and Autonomic Control
- Cardiac, Anesthesia and Surgical Outcomes
Mayo Clinic in Arizona
2017-2025
Mayo Clinic
2017-2025
WinnMed
2017-2024
Mayo Clinic in Florida
2017-2024
Health First
2024
Mayo Clinic Hospital
2023
Actelion (Switzerland)
2023
University of Minnesota
2023
Délégation Paris 6
2023
Université Paris-Saclay
2023
Background: We hypothesized that pulmonary venous hypertension in heart failure (HF) leads to predominate remodeling of veins and the severity is associated with (PH) HF. Methods: Patients HF (n=108; 53 preserved 55 reduced ejection fraction) PH (HF-PH; artery systolic pressure [PASP] ≥40 mm Hg) were compared normal controls (n=12) patients primary veno-occlusive disease (PVOD; n=17). In lung specimens from autopsy (control, HF-PH, 7 PVOD) or surgery (10 PVOD), quantitative histomorphometry...
Abstract Aims Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common associated with adverse outcomes in left heart (LHD). This study sought to characterize the pathophysiology of PVD across spectrum PH LHD. Methods results Patients PH-LHD [mean artery (PA) pressure >20 mmHg PA wedge (PAWP) ≥15 mmHg] controls free or LHD underwent invasive haemodynamic exercise testing simultaneous echocardiography, expired air blood gas analysis, lung ultrasound a prospective...
Background Microvascular inflammation may contribute to the pathogenesis of both heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH). We investigated whether biomarker C-reactive protein (CRP) was associated clinical characteristics, disease severity or PH in HFpEF. Methods Patients Phosphodiesterase-5 Inhibition Improve Clinical Status Exercise Capacity Diastolic Heart (RELAX) trial had baseline high-sensitivity CRP levels measured (n = 214). exercise...
The current Organ Procurement Transplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially important factors, such as severity of liver disease and pulmonary hypertension, are not included in the score, may affect survival. purpose this study was identify significant predictors waitlist mortality POPH.We performed a retrospective cohort database hemodynamics consistent POPH (defined mean...
BackgroundPulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled treprostinil (iTre) has been shown to improve functional ability and delay clinical worsening in PH resulting from ILD.Research QuestionDo higher dosages iTre have greater benefits preventing achieving improvement?Study Design MethodsPost hoc analysis INCREASE study, a 16-week double-blind, randomized, placebo-controlled trial ILD. Four groups were identified...
Background Inhaled treprostinil (iTre) is the only treatment approved for pulmonary hypertension due to interstitial lung disease (PH-ILD) improve exercise capacity. This post hoc analysis evaluated clinical worsening and PH-ILD exacerbations from 16-week INCREASE study change in 6-minute walking distance (6MWD) open-label extension (OLE) patients with less severe haemodynamics. Methods Patients were stratified by baseline vascular resistance (PVR) of <4 Wood units (WU) versus ≥4 WU ≤5...
Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis standard 12-lead ECG.
To evaluate the safety and efficacy of balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic hypertension (CTEPH) seen at a US medical center.Patients inoperable or residual postendarterectomy CTEPH who underwent BPA Mayo Clinic Rochester, Minnesota, between August 11, 2014, May 17, 2018, were included. Invasive hemodynamic, clinical, laboratory, echocardiographic data collected analyzed retrospectively.We identified 31 (26 5 CTEPH) 75 procedures performed staged manner...
Portopulmonary hypertension (POPH), pulmonary arterial (PAH) that develops in the setting of portal hypertension, affects 5%-6% patients with liver disease and is associated significant morbidity mortality. A mean pressure (mPAP) threshold 35 mm Hg used to stratify perioperative risk transplant eligibility treated POPH but does not take into account specific factors contribute elevation.In this case series, we describe characteristics posttransplant outcomes an mPAP ≥35 vascular resistance...
Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial (PAH). Data regarding use PAH-specific therapies in patients with PoPH are sparse as they usually excluded from clinical trials. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles newly initiating macitentan the USA using OPUS/OrPHeUS combined dataset.
Portopulmonary hypertension (POPH) is the presence of pulmonary arterial (PA) in patients with portal and associated significant morbidity mortality. In a cohort POPH patients, we describe clinical outcomes who underwent liver transplantation (LT).Retrospectively collected data from prospectively assembled all consecutive adults evaluated 3 transplant centers 1996 to 2019.From 228 50 LT. Significant hemodynamic improvement after PA-targeted therapy was observed, 58% receiving only...
Background. The current model for end-stage liver disease (MELD) exception policies portopulmonary hypertension (POPH) require serial right heart catheterizations (RHCs) every 3 mo to maintain points. RHC is necessary the initial diagnosis of POPH, but utility has not been studied. In patients with POPH MELD exceptions, we sought compare noninvasive and invasive hemodynamics determine sensitivity echocardiography detection hemodynamically severe that would preclude transplant. Methods. We...
Portopulmonary hypertension (POPH), pulmonary artery (PAH) that develops in the setting of portal hypertension, has long been significant interest to pulmonary, cardiology and hepatology communities. Optimal management POPH challenging define due lack evidence from clinical trials regarding PAH therapies uncertainty role liver transplantation (LT). Initially, high risk intraoperative early post-transplant death predominantly untreated patients with tempered consideration LT. More recently,...